STAT3 and P53: Dual Target for Cancer Therapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2020 Dec 29

PMID 33371351

Citations 28

Authors

Thu-Huyen Pham

Hyo-Min Park

Jinju Kim

Jin Tae Hong

Do-Young Yoon

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53 is considered the "guardian of the genome" that can protect cells against cancer by inducing cell cycle arrest followed by cell death. However, STAT3 is constitutively activated in several human cancers and plays crucial roles in promoting cancer cell proliferation and survival. Hence, STAT3 and p53 have opposing roles in cellular pathway regulation, as activation of STAT3 upregulates the survival pathway, whereas p53 triggers the apoptotic pathway. Constitutive activation of STAT3 and gain or loss of p53 function due to mutations are the most frequent events in numerous cancer types. Several studies have reported the association of STAT3 and/or p53 mutations with drug resistance in cancer treatment. This review discusses the relationship between STAT3 and p53 status in cancer, the molecular mechanism underlying the negative regulation of p53 by STAT3, and vice versa. Moreover, it underlines prospective therapies targeting both STAT3 and p53 to enhance chemotherapeutic outcomes.

Citing Articles

It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.

Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S J Neurooncol. 2025; .

PMID: 39821893 DOI: 10.1007/s11060-024-04930-w.

Probiotic Mixture Attenuates Colorectal Tumorigenesis in Murine AOM/DSS Model by Suppressing STAT3, Inducing Apoptotic p53 and Modulating Gut Microbiota.

Leung H, Lo E, Chen C, Zhang F, Felicianna , Ismaiah M Probiotics Antimicrob Proteins. 2024; .

PMID: 39641861 DOI: 10.1007/s12602-024-10405-1.

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.

Khuu A, Verreault M, Colin P, Tran H, Idbaih A Cells. 2024; 13(22).

PMID: 39594617 PMC: 11592788. DOI: 10.3390/cells13221869.

KIAA0040 enhances glioma growth by controlling the JAK2/STAT3 signalling pathway.

He J, Xue K, Fan F, Li L, Rao X, Liu W J Cell Mol Med. 2024; 28(8):e18332.

PMID: 38661644 PMC: 11044867. DOI: 10.1111/jcmm.18332.

Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets.

Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium Cancers (Basel). 2024; 16(5).

PMID: 38473265 PMC: 10931414. DOI: 10.3390/cancers16050901.

References

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

Mora L, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R . Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002; 62(22):6659-66. View

Savarese T, Campbell C, McQuain C, Mitchell K, Guardiani R, Quesenberry P . Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine. 2002; 17(6):324-34. DOI: 10.1006/cyto.2002.1022. View

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J . AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015; 7(314):314ra185. PMC: 5279222. DOI: 10.1126/scitranslmed.aac5272. View

Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L . Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2015; 22(4):868-76. PMC: 4809642. DOI: 10.1158/1078-0432.CCR-15-0481. View

Hang W, Yin Z, Liu G, Zeng Q, Shen X, Sun Q . Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1. Oncogene. 2018; 37(25):3384-3398. PMC: 6014869. DOI: 10.1038/s41388-017-0110-2. View

Lee J, Kim C, Lee J, Um J, Sethi G, Ahn K . Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells. Phytomedicine. 2019; 55:282-292. DOI: 10.1016/j.phymed.2018.06.038. View

Tantawy M, El-Sherbeeny N, Helmi N, Alazragi R, Salem N, Elaidy S . Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study. Mol Cell Biochem. 2020; 469(1-2):143-157. DOI: 10.1007/s11010-020-03736-4. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

10.

Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L . Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene. 2012; 31(46):4848-58. PMC: 3342476. DOI: 10.1038/onc.2011.644. View

11.

Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H . Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci. 2013; 104(8):1052-61. PMC: 7657144. DOI: 10.1111/cas.12176. View

12.

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K . STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011; 17(6):1452-62. PMC: 3077111. DOI: 10.1158/1078-0432.CCR-10-2694. View

13.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

14.

Lee C, Dhillon J, Wang M, Gao Y, Hu K, Park E . Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008; 68(21):8661-6. DOI: 10.1158/0008-5472.CAN-08-1082. View

15.

Duffy M, Synnott N, OGrady S, Crown J . Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020; 79:58-67. DOI: 10.1016/j.semcancer.2020.07.005. View

16.

Ray-Coquard I, Blay J, Italiano A, Cesne A, Penel N, Zhi J . Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012; 13(11):1133-40. DOI: 10.1016/S1470-2045(12)70474-6. View

17.

Rivlin N, Brosh R, Oren M, Rotter V . Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011; 2(4):466-74. PMC: 3135636. DOI: 10.1177/1947601911408889. View

18.

Hirano T, Ishihara K, Hibi M . Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19(21):2548-56. DOI: 10.1038/sj.onc.1203551. View

19.

Yun H, Kim S, Kwon Y, Kim C, Kang C, Kim E . Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells. Cancer Biol Ther. 2010; 10(4):354-61. DOI: 10.4161/cbt.10.4.12382. View

20.

OConnor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M . Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57(19):4285-300. View